












Bioorthogonal	 chemistry	 largely	 relies	 on	 the	 use	 of	 abiotic	 metals	 to	 catalyze	 new-to-
nature	 reactions	 in	 living	 systems.	 Over	 the	 past	 decade,	 metal	 complexes	 and	 metal-	
encapsulated	systems	such	as	nanoparticles	have	been	developed	to	unravel	the	reactivity	
of	 transition	 metals,	 including	 ruthenium,	 palladium,	 iridium,	 copper,	 iron,	 and	 gold	 in	
biological	systems.	Thanks	to	these	remarkable	achievements,	abiotic	catalysts	are	able	to	






Over	 the	 past	 decade,	 abiotic	 transition	metal-catalyzed	 reactions	 have	 successfully	 been	
introduced	 into	 living	 cells	 and	 organisms.	 With	 in	 vivo	 applications	 in	 mind,	 several	
challenges	 were	 identified	 and	 addressed:	 i)	 overcome	 the	 inherent	 cytotoxicity	 of	 the	
abiotic	 catalyst,	 ii)	 ensure	 the	 efficient	 metal	 uptake	 by	 the	 cell	 and	 iii)	 circumvent	 the	
deactivation	of	 the	 catalyst	 by	 thiols,	 proteins	 and	other	 cell	 components	 [1].	 To	 address	
these	 issues,	 several	 strategies	 were	 developed:	 i)	 metals	 were	 incorporated	 into	
nanoparticles	 or	 embedded	 in	 microspheres	 and	 resins	 (see	 sections:	 “Palladium	
nanoparticles”	 and	 “Copper	 and	 gold	 nanoparticles”;	 the	 catalyzed	 reactions	 are	
summarized	 in	 Table	 1)	 or	 ii)	 used	 as	 homogeneous	 metal	 complexes	 (see	 sections:	
“Homogenous	ruthenium	catalysts”,	“Homogenous	palladium	catalysts”	and	“Homogenous	
iron,	 iridium	 and	 gold	 catalysts”;	 the	 catalyzed	 reactions	 and	 complexes	 are	 collected	 in	
Table	 2).	 Most	 reactions	 developed	 to	 date	 are	 based	 on	 either	 a	 cleavage,	 or	 a	 cross-
coupling	 reaction.	 As	 a	 result,	 a	 variety	 of	 in	 vivo	 functions	 were	 established	 that	 are	
schematically	 presented	 in	 Figure	 1	 including:	 i)	 fluorescent	 labeling	 of	 cells,	 cell	
compartments	and	proteins,	ii)	synthesis	of	cytotoxic	agents	and	iii)	enzyme	rescue.	Several	
excellent	reviews	cover	bioorthogonal	reactions	[2-7]	or	bioorthogonal	protein	labeling	and	









Figure	 1.	 Strategies	 for	 the	 introduction	 of	 metal-catalyzed	 bioorthogonal	 reactions	 in	 cellulo/vivo.	
Biocompatible	 transition	 metal	 catalysts	 including	 metal-nanoparticles	 (NPs),	 NPs	 entrapped	 in	
microspheres	or	resins,	and	metal	complexes	are	taken-up	by	cells	or	 introduced	into	organisms.	These	
metal-platforms	 convert	 in	 cellulo/vivo	 various	 substrates	 through	 coupling	 or	 uncaging	 reactions	 into	




The	use	of	metal	nanoparticles	 (NPs)	 for	 in	cellulo	catalysis	was	 first	demonstrated	by	the	
Bradley	group	[13].	They	exploited	the	biocompatibility	of	polystyrene	microspheres	[14]	by	
entrapping	 Pd-NPs,	 creating	 fluorescently-labelled	 Pd0-microspheres	 [13,15].	 These	 Pd0-






well	as	 in	medical	applications	whereby	one	can	specifically	 target	an	organelle.	With	 this	
goal	in	mind,	Broceta	and	Bradley	et	al.	 implemented	a	Pd-NP	catalyzed	drug	release.	Pd0-
NPs	were	 linked	to	polyethylene	glycol	 (PEG)-polystyrene	resins	 forming	micrometer-sized	
beads	(~150	µm)	with	a	remarkable	biocompatibility	[16].	A	single	resin	bead	was	implanted	
into	the	yolk	sac	of	zebrafish	embryos.	The	embryos	developed	normally	without	any	signs	
of	 toxicity.	 To	 prove	 the	 in	 vivo	 activity	 of	 the	 Pd0-resin,	 the	 uncaging	 of	 a	
propargyloxycarbonyl	(poc)-protected	R110	was	assayed	within	the	yolk	sac	(Table	1,	entry	
3).	 This	 Pd0	 resin	 was	 also	 able	 to	 extracellularly	 uncage	 5-fluoro-1-propargyl	 (pro)-uracil	
(pro-5FU).	This	 lead	to	the	release	of	the	cytotoxic	drug	5-flurouracil	(5FU)	in	a	cancer	cell	
culture	of	either	HCT116	or	BxPC-3	cells	(Table	1,	entry	6)	[16].	
This	 therapeutic	 strategy	 was	 refined	 by	 combining	 a	 dual	 drug	 synthesis	 strategy	 with	




These	 tumor-targeting	microspheres	were	 used	 for	 the	 activation	 of	 two	 prodrugs	 inside	
U87-MG	 glioblastoma	 cells.	 Besides	 uncaging	 pro-5FU,	 the	 cytotoxic	 agent	 PP-121	 was	
produced	 via	 a	 Suzuki-Miyaura	 cross	 coupling	 reaction	 leading	 to	 increased	 cell	 death,	
compared	to	the	synthesis	of	either	5FU	or	PP-121	alone	(Table	1,	entry	6	and	10)	[17].	This	
approach	 illustrates	 the	 potential	 of	 metal-NPs	 for	 targeted	 drug	 delivery	 by	 converting	
innocuous	substrates	into	active	drugs	inside	tumor	cells.	
Subsequently,	Miller	et	al.		explored	a	Pd-NP	based	drug	synthesis	strategy	in	mice	[18].	For	
this	 purpose,	 the	 palladium	 complex	 bis[tri(2-furyl)phosphine]palladium(II)-dichloride	
(PdCl2(TFP)2)	 was	 encapsulated	 into	 poly(lactic-co-glycolic	 acid)-polyethyleneglycol	 (PLGA-




as	brain,	 skin,	 lung,	bone	marrow	and	heart.	 Interestingly,	 the	highest	 catalytic	activity	of	
Pd-NPs	for	the	release	of	either	fluorescent	R110	or	the	chemotherapeutic	drug	doxorubicin	
was	 observed	 in	 tumor	 tissue	 (Table	 1,	 entry	 1	 and	 2).	 Therefore,	 combining	 nano-
encapsulated	 Pd-NPs	 and	 caged	 doxorubicin	 helped	 to	 minimize	 systemic	 exposure	 and	






(CuAAC)	has	been	known	since	2002	 [24,25],	 it	was	hardly	used	 in	vivo	due	 to	 its	marked	
cytotoxicity	 [26].	 The	 incorporation	 of	 Cu	 into	 aspartate-containing	 polyolefins	 [20]	 or	
entrapping	 Cu	 in	 TentaGel	 resin	 [21],	 contributed	 to	 overcoming	 these	 biocompatibility	






Besides	Cu	and	Pd,	 gold	was	 immobilized	on	a	 solid	 support,	 a	polyethylene	glycol	 (PEG)-
grafted	 low-cross-linked	polystyrene	matrix	 [22].	This	Au-resin	was	employed	 for	 the	 local	
release	of	R110	 in	 the	brain	of	 zebrafish	 (Table	1,	entry	3)	as	well	as	 for	 the	activation	of	
structurally	 diverse	 prodrugs	 inside	 A549	 cancer	 cells	 (Table	 1,	 entry	 5,	 7	 and	 8).	 This	
demonstrates	 the	 potential	 application	 of	 Au-resin	 for	 in	 vivo	 drug-release	 [22].	
Furthermore,	 Tonga	et	 al.	 created	 controllable,	 Au-NPs	 by	 blocking	 the	 access	 to	 the	Au-
encapsulated,	catalytic	Ru-	or	Pd-complexes	[23].	This	‘gate-keeping’	was	achieved	through	
steric	 hindrance	 by	 supramolecular	 binding	 of	 cucurbit[7]uril	 onto	 the	 surface.	 The	 NPs	
were	activated	 through	 the	addition	of	 a	 competitor,	 1-adamantylamine	 to	unmask	alloc-
R110	 (by	Ru-	and	Pd-loaded	NPs)	and	 the	prodrug	pro-5FU	 (by	Pd-loaded	NPs)	 inside	 live	
HeLa	cells	(Table	1,	entry	1	and	6)	[23].	These	gated	NPs	reduce	the	interference	with	cell	
components,	 protect	 the	 metal	 from	 poisoning	 and	 increase	 the	 biocompatibility.	





Entry	 Reaction	 Catalyst	 Organism	 Ref.	
	 Allyloxycarbonyl	cleavage	 	 	 	
1	
































































	 Propargyloxycarbonyl	cleavage	 	 	 	
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of	bioorthogonal	organometallic	chemistry	 [27].	 In	2006,	 they	suggested	that	 the	complex	
[Cp*Ru(cod)Cl]	 Ru1	 (Cp*=pentamethylcyclopentadienyl,	 cod=1,5-cyclooctadiene,	 Table	 2,	
entry	1)	catalyzes	the	uncaging	of	alloc-protected	R110	inside	HeLa	cells,	while	not	affecting	
the	 cell	 viability	 [27].	 In	 2014	 and	 2017,	 they	 reported	 on	 significantly	 more	 active	 Ru-
pianostool	complexes	Ru2-Ru6	(Table	2,	entry	1	and	4)	catalyzing	alloc-unmasking		[28,29].	
Moreover,	alloc-protecting	groups	were	cleaved	off	from	DNA-binding	agents	such	as	4’,6-
diamidino-2-phenylindole	 (DAPI)	 and	 ethidium	 bromide	 inside	 chicken	 embryo	 fibroblasts	
(CEF)	and	the	kidney	epithelial	cell	line	Vero	(Table	2,	entry	2	and	3)		[30].		
Subsequently,	 the	 quinolone	 based	 Ru-complex	 was	 improved	 by	 reducing	 the	 π-
backbonding	of	 the	bidentate	 ligand	 (Ru2-Ru4)	and	 improving	 the	 in	vivo	R110	release	by	
130-fold,	 comparing	 Ru4	 to	 Ru1	 [28].	 Furthermore,	 Ru4	 unmasked	 efficiently	 alloc-
doxorubicin,	triggering	the	apoptosis	of	HeLa	cells	[28].	Very	recently,	the	activity	of	the	Ru-
complex	 was	 further	 enhanced	 tenfold	 by	 replacing	 the	 quinoline	 of	 Ru4	 with	 an	 8-






Ru7	 (Table	 2,	 entry	 1)	 [32].	 Such	 lipophilic	 cations	 are	 taken	 up	 by	mitochondria	 [33,34].	
After	 treading	 HeLa	 cells	 with	 Ru7	 and	 caged-R110,	 fluorescence	 was	 measured	 within	
mitochondria.	 This	 suggests	 that	 Ru7	 is	 present	 in	 the	 mitochondria,	 thanks	 to	 the	 TPP	
targeting	moiety	[32].	To	improve	the	traceability	of	Ru7,	a	pyrene	derivative	was	added	to	
afford	 Ru8	 (Table	 2,	 entry	 1),	 enabling	 fluorescent	 monitoring	 of	 the	 complex	 itself.	 As	
anticipated,	 both	 the	 catalyst	Ru8	 and	 R110	were	 localized	 inside	 the	mitochondria.	 The	
authors	 specifically	 depolarized	 mitochondria	 by	 deprotecting	 the	 proton	 ionophore	 2,4-
dinitrophenol	 (Table	 2,	 entry	 5)	 [35,36],	 demonstrating	 the	 potential	 of	 organelle-specific	
complexes	for	disturbing	and	modifying	biological	systems	[32].	
A	 different	 approach	 to	 target	 cell	 compartments	 and	 proteins	 was	 pursued	 by	 the	
Winssinger	 lab	 [37-39].	 A	 Ru-complex	 (Ru10,	 Table	 2,	 entry	 6)	 was	 linked	 to	 a	 peptide	
nucleic	acid	 (PNA)-probe	which	hybridizes	with	tissue	specific	miRNAs	[39].	The	Ru10-PNA	
and	 a	 fluorogenic	 rhodamine-PNA	 were	 injected	 into	 a	 one-cell	 zebrafish	 embryo.	 Using	











the	 assembly	 of	 an	 artificial	metalloenzyme	Ru13·Sav	within	 the	 periplasm	of	E.	 coli.	 The	
resulting	strain	catalyzed	the	ring	closing	metathesis	(RCM)	of	an	umbelliferone	precursor	in	
7	
the	periplasm	of	E.	 coli.	 The	catalytic	performance	of	Ru13·Sav	was	 improved	by	directed	
evolution	relying	on	the	fluorescence	of	the	formed	umbelliferone.	The	evolved	strain	was	




To	the	best	of	our	knowledge,	 the	 first	homogeneous	Pd-catalyzed	reaction	 in	cellulo	was	
reported	by	Lin	et	al.	 [41].	A	copper-free	Sonogashira	cross-coupling	reaction	was	used	to	
selectively	 label	 homopropargylglycine	E.	 coli	cells.	 Fluorescein	 iodide	was	 coupled	 to	 the	















complexes	 for	 a	 gain-of-function	 study,	 using	 a	 deprotection-strategy	 [47].	 The	
phosphothreonine	 lyase	 OspF	 was	 blocked	 by	 masking	 the	 catalytic	 Lys134	 with	 a	 poc-
group.	 The	 catalyst	 [Pd(η3-allyl)Cl]2	 Pd3	 (Table	 2,	 entry	 14)	 cleaved	 the	 poc-OspF	 and	
allowed	the	in	vivo	monitoring	its	substrate,	the	Erk	kinase,	in	HeLa	cells	[47].	This	gain-of-
function	 approach	 was	 extended	 by	 incorporating	 the	 UAA	 allenyl-tyrosine	 that	 can	 be	
uncaged	 thanks	 to	 homogeneous	 Pd-catalysts	 Pd3-Pd6	 (Table	 2,	 entry	 15)	 [48].	 The	
following	enzymes	were	rescued	by	allenyl-removal	through	Pd3-Pd6	in	HEK293T	cells:	Taq	
DNA	polymerase,	Src	kinase	and	the	anthrax	lethal	factor	endopeptidase	[48].	
Recently,	 cell-penetrating	 peptides	 were	 linked	 to	 a	 Pd-complex	 Pd7	 (Table	 2,	 entry	 13),	
improving	its	 internalization	(Table	2,	entry	13)	[49].	The	uncaging	of	poc-R110	in	prostate	
adenocarcinoma	(PC-3)	cells	was	demonstrated	[49].	The	peptide-based	platform	facilitates	





An	 iron(III)	 meso-tetraarylporphin	 Fe1	 (Table	 2,	 entry	 16)	 was	 shown	 to	 catalyze	 azide	
reduction	leading	to	the	release	of	R110	in	HeLa	cells	[52].	The	Ir-complex	Ir1	(Table	2,	entry	






on	 the	 liver	 or	 the	 intestine	 by	 using	 (2-6)-disialoglycoalbumin	 or	 galactosylglycoalbumin,	
respectively.	 These	 organ-targeted	 Au-complexes	 catalyzed	 an	 amide	 bond	 formation	
between	a	propargyl-ester	of	fluorescent	probes	(TAMRA-O-pro,	Cy7.5-O-pro)	and	surface-	




Since	 2014,	 the	 field	 of	 metal-catalyzed	 bioorthogonal	 reactions	 has	 made	 significant	
progress.	Initially,	it	was	demonstrated	that	metal-NPs	and	metal	complexes	can	uncage	or	




The	 exploitation	 of	 novel	 targeting	 and	 packaging	 strategies	 should	 further	 contribute	 to	









Entry	 Reaction	 Catalyst	 Organism	 Ref.	
	 Allyloxycarbonyl	cleavage	 Ruthenium	 	 	
1	
























































































































Entry	 Reaction	 Catalyst	 Organism	 Ref.	







































































































































































Entry	 Reaction	 Catalyst	 Organism	 Ref.	
	 Ring	closing	metathesis	 Ruthenium	 	 	
8	























































































































	 Suzuki-Miyaura	cross-coupling	 Palladium 	 	























Entry	 Reaction	 Catalyst	 Organism	 Ref.	
	 Propargyloxycarbonyl	cleavage	 Palladium	 	 	
13	
	

























































	 Bisazide	reduction	 Iron 	 	






































Entry	 Reaction	 Catalyst	 Organism	 Ref.	


































































































































This	 is	 a	 comprehensive	 review	 about	 artificial	 metalloenzymes	 (ArMs).	 Used	 scaffold	 proteins,	












































































































































The	 authors	 used	 Pd-complexes	 for	 gain-of-function	 studies	 in	 HeLa	 cells.	 Unnatural	 amino	 acids	
were	encoded	in	OspF	by	amber	stop	codon	suppression.	The	incorporation	of	a	protected	lysine	in	



























Au-complexes	were	 exploited	 to	 specifically	 label	 intestine	 and	 liver	 of	 live	mice.	 The	Au-complex	
was	 targeted	to	 these	organs	by	 linking	 it	 to	coumarin.	This	coumarin-Au-complex	binds	with	high	
affinity	 to	 albumins.	 In	 turn,	 the	 albumins	 were	 directed	 to	 liver	 and	 intestine	 by	 an	 N-glycan	
coating.		
	
	
	
	
